Home > Cardiology > AHA 2019 > New Approaches to CVD Risk Reduction > Inclisiran safely halves LDL-Cholesterol

Inclisiran safely halves LDL-Cholesterol

Presented By
Prof. R. Scott Wright, Mayo Clinic, Rochester, USA
Conference
AHA 2019
Trial
ORION-10

Prof. R. Scott Wright (Mayo Clinic, Rochester, USA) presented the latest data from the phase 3, randomised, placebo-controlled, double-blinded ORION-10 trial, testing the effect of the small interfering RNA (siRNA) inclisiran in patients with atherosclerotic cardiovascular disease (ASCVD) and elevated low-density lipoprotein cholesterol (LDL-C) [1]. With a follow-up of 18 months, inclisiran halved LDL-C levels compared with placebo. The safety profile was favourable.

ORION-10 randomised 1,561 ASCVD patients with elevated LDL-C (≥70 mg/mL) who were already taking maximum tolerated statins to receive either 4 injections (at 0, 3, 9, and 15 months) of placebo or of 300 mg inclisiran with a follow-up of 18 months. The co-primary endpoints were percentage of LDL-C change from baseline at day 510 and the average percentage change from day 90 to day 540.

At the study end at day 510, LDL-C was 58...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on